FY2025 · ended Dec 31, 2025 · Revenue $48.19B, -0.2% YoY · Filed Feb 11, 2026
Bristol-Myers Squibb Company (BMY) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $48.2 billion and net income of $7.1 billion. Free cash flow was $12.8 billion. As of Sep 30, 2026 it held $13.0 billion in cash and investments and $45.6 billion in total debt.
Revenue (TTM)
$50.03B
+4.2% vs year-ago TTM
Net income (TTM)
$9.24B
+53.1% vs year-ago TTM
Operating cash flow (TTM)
$10.65B
-35.9% vs year-ago TTM
Free cash flow (TTM)
$9.29B
-39.3% vs year-ago TTM
EPS (TTM)
$4.52
+52.3% vs year-ago TTM
Dividend per share
$2.49
+2.9% vs prior year
Shares outstanding
2.04B
+0.4% vs prior year
Net cash
$-32.62B
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BMY (NYSE), CELG-RI (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 14272
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $48.2B | $48.3B | $45.0B | $46.2B | $46.4B |
| Net income | $7.1B | -$8.9B | $8.0B | $6.3B | $7.0B |
| Diluted EPS | $3.46 | -$4.41 | $3.86 | $2.95 | $3.12 |
| Operating cash flow | $14.2B | $15.2B | $13.9B | $13.1B | $16.2B |
| Free cash flow | $12.8B | $13.9B | $12.7B | $11.9B | $15.2B |
| Total assets | $90.0B | $92.6B | $95.2B | $96.8B | $109.3B |
| Total liabilities | $71.5B | $76.2B | $65.7B | $65.7B | $73.3B |
| Stockholders' equity | $18.5B | $16.3B | $29.4B | $31.1B | $35.9B |
| Cash and investments | $11.1B | $11.2B | $12.6B | $9.3B | $17.0B |
| Total debt | $49.1B | $53.0B | $44.3B | $44.6B | $50.4B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 8, 2026 | May 5, 2026 |
| 10-Q | Quarterly report | Apr 30, 2026 | Mar 31, 2026 |
All 1003 Bristol-Myers Squibb Company SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.